Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Clin Pharm Ther ; 41(1): 64-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26778812

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: There is conclusive evidence demonstrating that formulary restrictions are associated with reduced utilization and pharmacy spending of the restricted drugs. However, prior efforts to implement restrictive formularies have been associated with inconsistent rates of therapy discontinuation and mixed impacts on adherence to therapy. Also, the impact of transferring patients from an already restrictive formulary to a more aggressive model has not been previously examined. This study evaluated the impact of implementation of a more restrictive formulary on therapy disruption, adherence rates, pharmacy costs and generic utilization among patients with common chronic conditions. METHODS: In 2014, CVS Health implemented Value Formulary (VF), a restrictive benefit design with the aim of reducing spending while preserving access to and adherence to essential therapy, was used. A retrospective cohort study was conducted to assess changes in therapy disruption rates, pharmacy costs and generic dispensing rate (GDR) (for continuers) and medication adherence (for initiators) following the implementation of VF. The study group was selected from members of three existing employer clients transitioned from standard formulary (SF) to VF on January 2014. The control population was a matched group of six employers with the same preperiod formulary structure, business unit, adherence programmes and patient out-of-pocket cost as the study group. The control group retained SF in 2014. To assess therapy disruption after VF implementation, we categorized patients by their subsequent medication use into three groups: (i) therapy stopped, (ii) therapy continued and (iii) therapy switched. Medication adherence was measured as monthly proportion of days covered (PDC). Pharmacy cost and GDR were measured per utilizer per month (PUPM). Rates of therapy disruption in study and control groups were compared using the chi-square test. Differences in monthly PDC between matched groups were evaluated using multivariate linear regression. Impact of VF on pharmacy cost and GDR was measured through segmented regression of interrupted time series data with generalized estimating equations. RESULTS AND DISCUSSION: A transition from SF to VF influenced drug coverage for approximately 13% of members (as their medications were either no longer covered, or covered restrictively under VF). Compared to patients whose plan sponsors retained SF, the patients that transitioned to VF had a modest (1·3%) but statistically significant increase in therapy discontinuation rates. This was offset by similarly modest improvements in adherence; patients who initiated therapy under VF demonstrated a 1·5% higher adherence to medications as compared to SF patients (P < 0·001). Medication costs in the VF group were lower by $20 PUPM (P < 0·001), and GDR was greater by 4·2% (P < 0·001). WHAT IS NEW AND CONCLUSION: Transition of patients to a more restrictive drug formulary led to modest therapy discontinuation, similarly modest improvements in medication adherence and substantial prescription drug cost savings. As healthcare payors search for ways to control the rapid rise in spending for medications without compromising quality, the Value Formulary can serve as a useful tool.


Subject(s)
Drugs, Generic/administration & dosage , Formularies as Topic , Medication Adherence , Prescription Drugs/administration & dosage , Adult , Aged , Cohort Studies , Drug Costs , Drugs, Generic/economics , Female , Humans , Insurance, Pharmaceutical Services/economics , Interrupted Time Series Analysis , Linear Models , Male , Middle Aged , Multivariate Analysis , Pharmaceutical Services/economics , Prescription Drugs/economics , Retrospective Studies
3.
Lik Sprava ; (1): 68-72, 1997.
Article in Ukrainian | MEDLINE | ID: mdl-9221150

ABSTRACT

A total of 198 cholera patients were studied for blood concentrations of electrolytes; the above patients were treated at Mykolaïv Cholera Hospital during an outbreak in 1995. It is advisable that blood plasma concentration of electrolytes be represented as mmol/kg of the mass of a cholera patient's body instead of mmol/l, to indicate disturbances in electrolytic balance. It is a matter of principle for the assessment of the patient's state to be done, first of all, before initiating the rehydration therapy treatments. Determinants of electrolytes in cholera patients got decreased not only in severe course of the illness but also in moderately severe one. Of all the electrolytes studied in blood plasma, it is in K+ and Cl- that deviations from the norm were at their greatest. Since electrolytic balance is a sensitive indicator of homeostasis of human organism it is useful to calculate the volume of salt solutions for the primary rehydration according to blood plasma concentration of Cl- in mmol/kg of mass of the patient's body. Lowering of electrolyte concentration in erythrocytes occurred only in severe course of cholera involving K+ only.


Subject(s)
Cholera/blood , Acute Disease , Cholera/complications , Cholera/therapy , Electrolytes/blood , Fluid Therapy , Humans , Water-Electrolyte Imbalance/blood , Water-Electrolyte Imbalance/etiology , Water-Electrolyte Imbalance/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...